Understanding Chronic Rhinitis and Treatment Challenges
Chronic rhinitis, a prevalent condition affecting a considerable portion of the population, encompasses allergic, nonallergic, and mixed forms. In Taiwan alone, over 26.3% of individuals experience its debilitating symptoms, which typically include persistent rhinorrhea (runny nose), nasal congestion, itching, and sneezing. While medical therapies, such as topical nasal steroids and oral antihistamines, are considered the frontline treatment, a significant number of patients find these interventions insufficient to manage their chronic symptoms. For these individuals, surgical or interventional approaches become necessary considerations.
Historically, more invasive surgical procedures like vidian neurectomy have been employed. However, these interventions carry a considerable risk of adverse effects, including bleeding, the formation of nasal crusting, altered sensation or numbness within the nasal passages, and even dry eyes due to potential disruption of parasympathetic nerve pathways. More recently, office-based techniques for posterior nasal nerve (PNN) ablation, such as cryotherapy and temperature-controlled radiofrequency, have emerged in other regions. These methods offer less invasive alternatives, but their widespread availability, particularly in many Asian countries, remains a limiting factor. This gap in accessible, effective treatments for chronic rhinitis has driven the exploration of new methodologies.
A Groundbreaking Study in Taipei
A retrospective single-center study, conducted in 2025 at Shuang Ho Hospital, Taipei Medical University, Taiwan, investigated the efficacy and safety of a novel blue-laser-based approach. The research involved 42 adult patients, aged between 18 and 65 years, all of whom had been diagnosed with chronic rhinitis and nasal congestion that had proven refractory to more than three months of conventional intranasal steroid and antihistamine therapy. A crucial inclusion criterion was the confirmation of allergic rhinitis through elevated immunoglobulin E (IgE) levels. Furthermore, all participants presented with a total 24-hour reflective Total Nasal Symptom Score (rTNSS) greater than 5, alongside moderate-to-severe rhinorrhea and mild-to-severe congestion, indicating a significant burden of disease.
The study employed a combined procedure: blue-laser inferior turbinate reduction (BITR) alongside blue-laser posterior nasal nerve neurolysis (BPN3), utilizing a 445-nm blue laser. Patient outcomes were meticulously tracked by recording rTNSS and Nasal Obstruction Symptom Evaluation (NOSE) scores at three key junctures: baseline, one month post-operatively, and six months post-operatively.
The Dual-Layer Nerve Modulation Technique
The core innovation of this study lies in the "dual-layer nerve modulation" technique. This approach was systematically applied to all 42 participants. Initially, the procedure involved superficial treatment of the PNN plexus, targeting nerve fibers located at the lateral posterior aspect of the middle meatus, as well as the posterior ends of both the middle and inferior turbinates. This initial phase aimed to desensitize the more superficial neural network contributing to rhinitis symptoms.
Following this superficial modulation, the technique progressed to a deeper submucosal ablation of the main nerve trunks. These deeper nerves were targeted at their origins within the posterior regions of the middle and inferior turbinates. This comprehensive approach ensures that both the immediate and deeper neural pathways involved in rhinitis symptom generation are addressed.
Complementing the neurolysis, the blue-laser inferior turbinate reduction (BITR) was performed. This aspect of the procedure utilized a 2.5 W super-pulse contact blue laser. The laser was applied submucosally to the anterior one-third of the inferior turbinate. The primary goal of BITR is to debulk the hypertrophied inferior turbinate tissue, a common contributor to nasal congestion, while critically preserving the overlying mucosal lining. This mucosal preservation is vital for maintaining nasal function and preventing complications.
The choice of a 445-nm blue laser is significant. The authors of the study emphasize its unique photoangiolytic properties. This characteristic allows for highly accurate and bloodless tissue ablation, a considerable advantage when operating in the highly vascularized posterior nasal region. The precision offered by the blue laser minimizes collateral damage to surrounding tissues and reduces intraoperative bleeding, contributing to a safer and more efficient procedure.
Remarkable Symptom Improvement and Safety Profile
The results of the study paint a compelling picture of the effectiveness of this dual-layer nerve modulation technique. At baseline, patients reported a mean rTNSS of 7.9 (± 2.1) and a mean NOSE score of 69.3 (± 11.4). These scores reflect a substantial level of distress and functional impairment due to their chronic rhinitis.
The impact of the combined BITR and BPN3 procedure was observed dramatically at the one-month follow-up. The mean rTNSS plummeted to 1.8 (± 1.7), representing an approximate reduction of 78.5% from baseline. Concurrently, the mean NOSE score decreased to 7.0 (± 6.5), an impressive reduction of approximately 89.9%.
The positive effects were not transient. At the six-month follow-up, the improvements remained substantial. The mean rTNSS was recorded at 1.9 (± 1.8), indicating a sustained relief of approximately 76.0% compared to the initial scores. Similarly, the mean NOSE score remained low at 6.6 (± 5.3), signifying a sustained improvement of about 92.0%. These sustained reductions in both objective and subjective symptom measures underscore the long-term benefits of the procedure.
Crucially, the safety profile of the combined technique was excellent. The study reported that any instances of crusting were minor and transient, resolving without intervention. More importantly, no serious complications were observed throughout the entire study period. This finding is particularly encouraging given the historical concerns associated with more invasive nasal procedures. The dual-layer nerve modulation, by targeting both superficial and deep neural elements, coupled with the precise tissue reduction of the inferior turbinate, appears to offer a robust yet gentle solution.
Expert Commentary and Future Outlook
The researchers behind the study have highlighted the synergistic effect of their dual-layer nerve modulation approach. They posit that by addressing the extensively distributed PNN fibers at multiple depths, the BPN3 component effectively targets the neurological underpinnings of chronic rhinitis. When combined with the turbinate reduction, which addresses the physical obstruction often contributing to congestion, the procedure achieves a comprehensive solution.
The authors’ emphasis on the blue laser’s unique properties—its ability to facilitate bloodless and accurate ablation—is a key takeaway. This technical advantage is paramount in the delicate environment of the nasal cavity, where precision is critical to avoid damage to essential structures. The combination of safety and effectiveness demonstrated by BPN3 and BITR positions this minimally invasive option as a significant advancement for patients struggling with medication-refractory chronic allergic rhinitis.
While this study represents a significant step forward, it is important to acknowledge its retrospective nature and single-center design. Future prospective, multi-center randomized controlled trials will be essential to further validate these findings and compare the blue-laser technique against existing treatments, including other less invasive nerve ablation methods. Such studies would provide a broader understanding of its long-term efficacy, optimal patient selection criteria, and potential for wider adoption.
The implications of this research extend beyond the immediate patient cohort. As the global prevalence of chronic rhinitis continues to be a significant public health concern, the development of safe, effective, and accessible treatment options is paramount. The success of the blue-laser dual-layer nerve modulation technique could offer a much-needed alternative for countless individuals worldwide who are seeking relief from the persistent and often frustrating symptoms of chronic rhinitis, potentially reducing their reliance on long-term medication and improving their overall quality of life. The availability of such advanced, yet minimally invasive, therapeutic modalities represents a beacon of hope in the ongoing battle against this common and impactful condition.
